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Abstract Poor medication adherence is a major problem in
chronic diseases such as osteoporosis that may partially be due
to unaddressed patient values and preferences. Data on patient
preferences could help clinicians to improve medication ad-
herence and could also be useful in policy decisions and
guideline development. This paper aims to identify literature
reporting on the preferences of patients for osteoporosis drug
medications. Several methods have been used to elicit patient
preferences for medications and their characteristics including
qualitative research, survey with ranking/rating exercises,
discrete-choice experiments and clinical studies (crossover
designs, open-label study). All these studies revealed that os-
teoporotic patients have preferences for medications and their
attributes, in particular for less-frequent dosing regimens. In-
terestingly, variations in the preferences of patients were ob-
served in most studies, suggesting the importance to take into
account individual preference in decision-making to improve
osteoporosis care.
Keywords Crossover designs . Discrete-choice experiment .
Drug therapy . Osteoporosis . Preferences . Review .
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Introduction
Osteoporosis represents an increasing public health problem,
especially in the Western world. For the year 2010, it was
estimated that about 27.5 million of people from the European
Union have osteoporosis [1], resulting in approximately 3.5
million new fractures. Despite the fact that several drugs have
demonstrated to be safe and effective in reducing the risk of
fractures [2], adherence to medications remains poor and sub-
optimal [3], with substantial clinical and economic implica-
tions [4]. Poor adherence to therapy may partially be due to
unaddressed patient values and preferences [5].
Understanding what patients prefer and involving them in
clinical decision-making could lead to improved satisfaction
with therapy and hence medication adherence [6]. Patient per-
ceptions and preferences with osteoporosis medications were
shown to impact adherence behaviour [7••] and discontinua-
tion rates [8]. The patient’s perspective is now becoming in-
creasingly important in the design and assessment of
healthcare interventions [9]. Patients want to be informed by
their doctors and play an active role in clinical decision-
making [10]. Therefore, in recent years, there has been a
growing interest in studies to elicit preferences for healthcare
interventions. There are different ways to elicit patient prefer-
ences including qualitative research, survey with ranking/
rating exercises, discrete-choice experiments and clinical stud-
ies (such as crossover or open-label study).
With the development of new osteoporosis medications
that differ mainly according to mode of administration, it is
not surprising that several studies have been conducted to
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elicit patient preferences for osteoporosis medications and un-
derstand the so-called attributes or factors that contribute to
preferences. Reviewing these studies and reporting their find-
ings could have substantial potential for clinicians towards
improving poor medication adherence and could also be very
useful for policy decisions and guideline development [11].
This paper was therefore designed to review studies that
assessed preferences in osteoporosis. A secondary aim was
to discuss how preference could be incorporated in clinical
decision-making.
Patients’ Preferences for Osteoporosis Medications
A review of published studies that describe patient pref-
erences for osteoporosis drug treatment was conducted
in PubMed. The search terms were ‘preference* [title/
abstract] OR satisfaction [title/abstract] AND ‘osteopo-
rosis [MESH term]’, and all articles published until
May 1, 2015, were included. We only included original
research that looks at preferences for osteoporosis med-
ications and/or medication attributes. We followed the
operational definition of preference given by Joy et al.
[11]: ‘given a choice, the selection of an alternative’.
We therefore included studies that looked at the choice
of patient between alternatives. We also included pref-
erence studies that assessed preferences for medication
attributes using hypothetical treatment options and stud-
ies that were interested in preferences for medication
characteristics. Non-medication interventions were ex-
cluded. Abstract and title screening was initially per-
formed, followed by a full-text screening. References
of identified articles were searched for additional arti-
cles and completed by authors’ knowledge of the pub-
lished literature. Data were collected on study authors,
country, publication year, method, sample size, funding
and main findings. The number of medication attributes
was included for surveys, and interventions were includ-
ed for clinical studies.
The PubMed search yielded 246 articles. A total of 23
articles met our inclusion criteria. Ten studies used a question-
naire or interviews to elicit preferences for medication attri-
butes. Among these, 4 studies specifically aimed to identify
the attributes that play a role to preferences of osteoporotic
patients for medication attributes, 4 used conjoint analysis
methods to elicit the trade-offs patients make between attri-
butes and 2 were interview-based surveys to elicit preferences
between two medications. The remaining 13 articles investi-
gated patient preferences between two real-life interventions
using an open-label study (n=7) or crossover design (n=6).
Tables 1 and 2 summarize the characteristics and main find-
ings of all these studies.
Importance of Medication Attributes
Four studies assessed the importance of osteoporosis medica-
tion attributes [12, 13, 14•, 15•]. The PREFER study was a
large-scale survey that was conducted in the USA [12] and in
five other countries [13]. Participants from these countries
were administered an online questionnaire in which they were
asked to rate and rank the importance of seven (or eight)
medication attributes in determining their preferences for os-
teoporosis medications. In Hiligsmann et al. [14•], patient
group discussions were conducted to prioritize a list of 12
potentially important medication attributes identified from
the literature and discussion with clinicians. A total of five
focus groups were conducted in the Netherlands and Belgium.
Silverman et al. [15•] asked participants to evaluate the rela-
tive weight of specific statements using MaxDiff analyses. In
MaxDiff analyses, participants receive a list of statements and
are asked to indicate the most (and the least) important one.
As shown in Table 1, in all these studies, drug effectiveness
was the most important attribute for the patients followed by
side effects. Out-of-pocket costs and mode/frequency of ad-
ministration were also considered important. Variations in the
preferences of patients were reported. Hiligsmann et al. [14•]
revealed different findings across the focus groups. The coun-
try system could also influence the preferences. In the Neth-
erlands, where patients have no out-of-pocket contribution,
the cost attribute was not as important as in Belgium [14•].
Silverman et al. [15•] also reported a significant impact of age,
income, education and prior fractures on overall ranking but
not of racial/ethnic differences.
Conjoint Analyses Studies
Four studies used conjoint analysis methods to assess trade-off
that patients make between medication attributes [16–18,
19••]. Fraenkel et al. [18] used ‘adaptive conjoint analyses’
to dete rmine the t rea tment preferences for ora l
bisphosphonates by frequency of administration. Results sug-
gested that preferences are strongly influenced by route of
administration. Three discrete-choice experiments (DCEs)
were conducted [16, 17, 19••]. A DCE is a form of conjoint
analysis that describes an intervention by its attributes (e.g.
effectiveness, side effects, costs) and reports how patient’s
preference for an intervention is influenced by the type and
levels of these attributes [20]. In the DCEs, patients were
asked to choose between two unlabelled drug treatments (A
and B) and sometimes a third ‘no treatment’ option. De
Bekker-Grob et al. [17] evaluated the preferences of patients
for osteoporosis treatments in the Netherlands. All attributes
(i.e. effectiveness, side effects, treatment duration, route of
drug administration, and out-of-pocket costs) were shown to
be important. The timing of administration was however lim-
ited to a maximum of 4 months. New therapies with longer
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dosing intervals have recently become available, and prefer-
ences for these new administration schemes should be inves-
tigated. Darba et al. (2010) also used a DCE to investigate the
importance of different treatment aspects in Spain. Only three
attributes were however included in the experimental design
(i.e. type of drug administration, place of administration, cost)
and were all important. More recently, Hiligsmann et al. [19••]
conducted a DCE with Belgian patients. This study confirms
expected results that patients prefer treatments offering higher
efficacy, lower costs and less-frequent dosing regimens. This
study does, in addition, evaluate additional administration
routes and the side effects deemed important by patients
[21•]. Patients had a preference for a 6-month subcutaneous
injection and weekly oral tablet compared with oral tablet and
yearly intravenous. Using a mixed logit model that allows
coefficients to vary between patients, this study also revealed
that preferences could substantially differ between patients.
Structured Interviews
There were 2 studies conducting structured interviews by
phone [22] or from a panel of patients currently using oral
bisphosphonates [23]. In Keen et al. [22], 50 % of the partic-
ipants of the interviews previously or currently used oral
bisphosphonates. Participants were asked to choose between
two oral treatments, a weekly oral tablet with proven efficacy
at the spine and hip and a monthly oral tablet with no proven
efficacy at the hip. Most participants chose the treatment with
proven efficacy at both hip and spine, even though the other
choice was the less frequently dosed treatment [22, 23]. Pre-
vious bisphosphonate use did not influence preference; how-
ever, it affected ‘intention to use’ significantly in a positive
direction [22].
Clinical Studies
Most preference studies identified in this review were clinical
studies where patients were asked to describe their preferences
and satisfaction to treatment that they had received or tested.
Most studies have focused on the influence of dosing frequen-
cy (daily, weekly, monthly, bi-annually or annually) for ther-
apy on patient preference. Studies were either crossover or
open-label studies.
In the clinical studies, the following questionnaires were
used: Beliefs about Medicines Questionnaire (BMQ, includ-
ing 22 questions in the followingmajor domains: the necessity
of the prescribed medication to manage osteoporosis now and
in the future, concerns about the potential adverse effects of
taking the prescribed medication, preference for one medica-
tion over the other) [24, 25], Preference Satisfaction Question-
naire (PSQ, measuring preference, pill satisfaction, injection
satisfaction, pill bother and injection bother) [25–28], ques-
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Osteoporosis Patient Satisfaction Questionnaire (OPSATQ)
[26, 32] and Treatment Satisfaction Questionnaire for Medi-
cation (TSQM; consisting of 14 items to assess an individual’s
perception of effectiveness, side effects, convenience and
global satisfaction) [33].
Overall, the crossover studies showed a preference for 6-
monthly injections or once-monthly oral bisphosphonates
over once-weekly oral bisphosphonates [25, 27, 29, 30], or a
preference for once-weekly oral bisphosphonates over daily
oral bisphosphonates [31, 34]. One study compared chewable
and sachet calcium/vitamin D supplementation and found a
preference for the chewable variant [24]. The sequence of
treatments did not influence preferences [27, 30, 31]. Partici-
pants considered the lower dosing frequency of oral
bisphosphonates to be more convenient [27, 29, 30, 34]. Par-
ticipants were asked for perceived long-term adherence in 3
studies [25, 31, 34] and thought that the less-frequent dosing
regimen would lead to better long-term adherence. Some of
the crossover studies also tested for adherence [24, 25, 34] and
found a lower adherence in the less preferred treatment.
The open-label studies included patients who had been on
weekly bisphosphonates and who were switched to a monthly
regimen [26, 32, 35] or to another bisphosphonate or
denosumab [33] and showed a preference for the less fre-
quently administered treatment. Kendler et al. (2011) found
no difference in perceived necessity of osteoporosis treatment
between 6-monthly injections or weekly oral bisphosphonates
at baseline, but after 6 months, the perceived necessity was
higher in the denosumab group. Concern about side effects
did not differ between groups. In the study of Kastelan et al.
[35], compared to patients who refused to participate in
the study (n=67) and those who did not start monthly
ibandronate according to the suggestion of their attending
doctor (n=15), enrolled patients (n=258) stated less satisfac-
tion with the weekly bisphosphonates at baseline (p<0.001)
and were more likely to have adverse events during weekly
treatment. Patients reported that the once-monthly dosing reg-
imen better fitted their lifestyle and they preferred the less-
frequent dosing and thought it to be an easier regimen to
follow at long term. One study was a randomized clinical trial
comparing a weekly oral and a yearly intravenous bisphos-
phonate, and patients completed the questionnaire without
knowing their randomization. The preference for the yearly
administered medication was highest [36].
Use of Preferences in Clinical Decision-Making
Over the last century, the provision and evaluation of medical
care saw several paradigm shifts. While medicine relied for
ages on experience-based medicine, a shift towards evidence-
based medicine followed by evidence-based practice was seen
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practice was largely based on efficacy/effectiveness, safety
and increasingly cost-effectiveness, Carr et al. [37] already
recognized in 2001 that diseases do not exist in a medical
vacuum and that it is impossible to separate disease from an
individual’s personal and social context. On this line, the
twenty-first century is becoming the age of preference-based
medicine in which the clinicians become the experts on the
medical options, while patients (and their families) bring in
their values and preferences. This ‘patient centered care’ re-
quired a whole new area of research into patient-reported out-
comes and even more into methods to assess preferences and
in approaches to incorporate preferences in the medical office.
Preference studies on medication choices, as reviewed above,
are valuable to assess which treatments or which treatment
attributes are valued (or not) by patients at the group level.
Such studies are of great value as they learn that patients’
values differ from those of doctors and reveal what aspects
of health, treatment or care patients specifically value. Such
insights can help when developing treatment guideline (that
largely ignores preferences) but can also be an impetus to
account for patient needs when developing drugs, also for
seemingly futile aspects like treatment administration and fre-
quency of dosing. However, the study by Hiligsmann also
emphasized that preferences elicited at the group level show
large variance around the estimated coefficients, indicating
heterogeneity in preferences between patients. Therefore, in
clinical practice, tools are needed that can reveal preferences
of individual patients in decisions and support shared deci-
sion-making. In osteoporosis, several decision aids are avail-
able already, some supporting the patients in the decision on
whether or not to start a treatment for (prevention of) osteo-
porosis, some supporting the decision to choose a specific
drug, characterized by its different attributes, and others both
aspects of decision [5]. Such decision tools can be either ap-
plied in the consultation room by the physician and research
nurse or can be used by patients themselves as self-standing
online tools. Although a systematic Cochrane review on deci-
sion aids showed evidence that decision aids improve knowl-
edge, reduce decisional conflict and succeed in aligning re-
ceived care with personal values [38], another study revealed
that in 1000 office visits in which 3500 medical decisions
were made, less than 10 % of decisions met the minimum
for informed decision-making [39]. Thus, it appears that even
when we really believe in preference-based care, lots of work
is still needed [40].
Discussion
Our review identified several studies that assessed preferences of
osteoporotic patients for medications. Different methods have
been used including clinical studies and stated-preference
methods. In clinical studies, different questionnaires are
available to test for preferences and/or convenience. Eliciting
preferences seems however not always a straightforward pro-
cess, as revealed by studies comparing preferences for weekly
and monthly oral tablet. Crossover or open-label studies com-
paring once-monthly and once-weekly oral bisphosphonates re-
vealed a preference for the once-monthly oral tablet [27, 29, 30,
35] in patients who had taken both regimens. However, when
patients were informed about the limited evidence of efficacy of
the once-monthly oral regimen, the preference was in opposite
direction with most patients preferring once-weekly oral bis-
phosphonate with proven efficacy at both the spine and the hip
[22, 23]. In addition, in recent years, an increased use of stated-
preference methods like DCEs to elicit preferences in healthcare
has been seen [41], which could be interesting to reveal prefer-
ences even before receiving a therapy. Formal stated-preference
methods use survey/question to elicit patient preferences for
hypothetical treatment options in an experimental framework
and allow to assess the importance of medication attributes
and trade-offs that patients make between them. Alternatively,
revealed preference methods are based on observed data related
to patients’ actual choice. Patients’ choice in healthcare however
does not often reflect what the patient prefers given imperfect
information and revealed preferencemethods can also not reveal
which factors influence the decisions.
One limitation of the design of the clinical studies (especial-
ly in open-label studies) is the selection bias. Some of the open-
label studies that switched from a baseline regimen to the study
medication included patients with higher rates of dissatisfac-
tion and more side effects at baseline, whereas the patients who
were not included did better on the baseline regimen [34].
There is no information available about the preference of the
patients who were not included, who did have less side effects
and who might have a different preference. Anyhow, in the
crossover and open-label studies, the preferred regimen was
associated with higher convenience and higher observed ad-
herence. Moreover, patients perceived that their long-term ad-
herence would be better with the preferred regimen. Taking
into account the preference of the individual patient would
implicate explaining about the different dosing regimens and
means of application, the potential benefits of the different
regimen and the potential side effects. Prescribing the preferred
treatment could improve (long-term) adherence; however, we
are lacking evidence of clinical studies.
There are some potential limitations to our review. First,
although we reviewed the literature using PubMed, we did not
perform a complete systematic review following the PRISMA
statement. Since our key words were perhaps limited and we
limited our search to one database, we probably missed some
papers that however would not have impacted ourmain findings.
Second, we did not provide a quality assessment of the papers.
Currently, there are no general guidelines for assessing the qual-
ity of stated-preference studies [14•]. Despite these potential lim-
itations, reviewing preferences provide interesting information
61 Page 8 of 10 Curr Rheumatol Rep (2015) 17: 61
for clinicians and decision-makers which should be aware that
osteoporotic patients could reveal preferences for medications
and their characteristics. Furthermore, taking into account these
preferences when choosing for a treatment for osteoporosis
could lead to a higher adherence and compliance. With the in-
creasing importance of the patient perspective and as more stud-
ies report on patient preferences, we could also expect that re-
views of preferences will be more often made in the future.
Conclusions
This review revealed that osteoporotic patients report prefer-
ences for medications and their characteristics. Although effec-
tiveness and side effects were, not surprisingly, important con-
siderations in treatment preferences, frequency of administra-
tion (and in particular less-frequent dosing regimens) is also
highly valued by patients, as suggested by Bansback et al. in
rheumatic diseases [42•]. Understanding patients’ preferences
and incorporating them in clinical decision-making could lead
to improved osteoporosis care. Patient perceptions and prefer-
ences with osteoporosis medications have been shown to im-
pact adherence behaviour [7••] and discontinuation rates [8].
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